Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.07), Briefing.com reports. Exelixis had a net margin of 9.58% and a return on equity of 6.53%. The company had revenue of $471.90 million […]
William Blair restated their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report published on Monday morning, RTT News reports. William Blair also issued estimates for Exelixis’ Q3 2023 earnings at ($0.05) EPS and FY2023 earnings at $0.45 EPS. EXEL has been the topic of several other research reports. […]
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price traded down 6.1% on Monday . The company traded as low as $19.12 and last traded at $19.83. 2,044,579 shares changed hands during trading, a decline of 23% from the average session volume of 2,657,925 shares. The stock had previously closed at $21.11. Wall Street Analyst […]
LSV Asset Management lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 39.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,267,475 shares of the biotechnology company’s stock after selling 838,909 shares during the quarter. LSV Asset Management owned […]